Role of Extracellular vesicle microRNAs and RNA binding proteins on glioblastoma dynamics and therapeutics development

The intricate interplay between extracellular vesicles (EVs), microRNAs, and RNA binding proteins (RBPs) constitutes a crucial mechanism in glioblastoma pathogenesis. The regulated sorting of microRNAs into EVs, influenced by RBPs and specific RNA motifs, plays a pivotal role in intercellular communication and significantly impacts various biological processes associated with glioblastoma development. Glioblastoma cells exploit this mechanism to exchange genetic information, influencing tumor progression, heterogeneity, and treatment response. This review highlights the dysregulation of EV-encapsulated microRNAs as a modulator of key signaling the disease. The versatile role of EV-microRNAs extends to impacting glioma behavior, immune response, angiogenesis, and serving as valuable diagnostic, prognostic, and therapeutic targets. Furthermore, the involvement of RBPs in microRNA sorting into EVs presents therapeutic targets that bridge cellular signaling with EV cargo composition. This comprehensive understanding and the strategic approaches targeting the complex interactions within the EV-microRNA-RBP axis opens promising avenues for advancing diagnostics and developing targeted therapies against the heterogeneous nature of glioblastoma and enhance treatment efficacy. The personalized and effective treatment strategies that may emerge from this research have the potential to revolutionize the approach to combating this devastating brain cancer. • miRNAs sorted into EVs play a critical role in glioblastoma progression and treatment outcomes. • EV containing miRNAs impact glioma behavior, immune response and serve as diagnostic, prognostic and therapeutic targets. • Dysregulation of EV encapsulated miRNAs modulate key signaling in glioblastoma. • RBPs sorting miRNAs into EVs are therapeutic targets and bridging cellular signaling with EV cargo composition. • Understanding EV-miRNA-RBP axis opens avenues for diagnostics and targeted therapies in glioblastoma.